Arcus Biosciences, Inc. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Arcus Biosciences, Inc. (RCUS) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $8.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-08-05
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-30 was $8.00M, a 94.74% decline year-over-year.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-03-31 was $10.00M, a 50.00% decline year-over-year.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $22.00M, a 633.33% increase year-over-year.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $20.00M, a 51.22% decline year-over-year.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $214.00M, a 3.38% increase from fiscal 2024.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $207.00M, a 158.75% increase from fiscal 2023.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $80.00M, a 8.11% increase from fiscal 2022.
- Arcus Biosciences, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $74.00M.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.00M 10-Q · filed 2026-08-05 | $18.00M 10-Q · filed 2026-08-05 | $40.00M derived: sum of 3 quarters · filed 2026-08-05 | $60.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-05 | $32.00M derived: sum of 2 quarters · filed 2026-05-05 | $52.00M derived: sum of 3 quarters · filed 2026-05-05 | $204.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $42.00M derived: sum of 2 quarters · filed 2026-02-25 | $194.00M derived: sum of 3 quarters · filed 2026-08-05 | $214.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | $20.00M 10-Q · filed 2025-10-28 | $172.00M derived: sum of 2 quarters · filed 2026-08-05 | $192.00M 10-Q · filed 2025-10-28 | $195.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $152.00M 10-Q · filed 2026-08-05 | $172.00M 10-Q · filed 2026-08-05 | $175.00M derived: sum of 3 quarters · filed 2026-08-05 | $216.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $20.00M 10-Q · filed 2026-05-05 | $23.00M derived: sum of 2 quarters · filed 2026-05-05 | $64.00M derived: sum of 3 quarters · filed 2026-05-05 | $92.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $44.00M derived: sum of 2 quarters · filed 2026-02-25 | $72.00M derived: sum of 3 quarters · filed 2026-02-25 | $207.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $41.00M 10-Q · filed 2025-10-28 | $69.00M derived: sum of 2 quarters · filed 2025-10-28 | $204.00M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $28.00M 10-Q · filed 2025-08-06 | $163.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $135.00M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $80.00M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $74.00M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |